{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
niacin
to a specific field?
Status:
Possibly Marketed Outside US
Source:
MCM Topical Gel Patch by FORREAL PHARMACEUTICALS LLC
(2023)
Source URL:
First approved in 2023
Source:
MCM Topical Gel Patch by FORREAL PHARMACEUTICALS LLC
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Omega-3 Support by TMIG, Inc.
(2015)
Source URL:
First approved in 1961
Source:
ADELGADINA by ProMex LLC
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Nicotinyl methylamide (N-methylnicotinamide) is an experimental drug with no approved indication or marketed formulation. Nicotinyl methylamide is a metabolite of niacin (or nicotinamide) and is commonly found in human urine. However low levels of urinary excretion of N-methylnicotinamide indicates niacin deficiency. In patients with liver cirrhosis nicotinamide methylation is increased leading to a rise in urinary N-methylnicotinamide. The hyperfunction of this methylating pathway might play a protective role against the toxic effect of intracellular accumulation of nicotinamide deriving from the catabolic state of cirrhosis. N-methylnicotinamide is known to inhibit choline transport and reduce choline clearance out of the brain. N-methylnicotinamide has been found to be a microbial metabolite. N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats. N-methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. The antithrombotic effect of N-methylnicotinamide is accompanied by platelet inhibition and enhanced fibrinolysis, due to the decrease production of plasminogen activator inhibitor -1.
Status:
Possibly Marketed Outside US
Source:
Teonicon by Bracco [Italy]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
There are a few information in the literature about pimephylline nicotinate. The metabolites of this compound were determined in the rats.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hypolipidemic agent, Nicomol is an ingredient of Cholexamin in Japan. Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched by KYORIN Pharmaceutical in 1971. It is indicated for the treatment of hyperlipemia, improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome.
Status:
Possibly Marketed Outside US
Source:
Pemix by Prodes [Spain]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pirozadil (Pemix), a hypolipidemic agent that improves cerebral blood flow and Inhibits platelet aggregation. This drug was studied for the treatment of patients with Type IIa hyperlipoproteinemia.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Acipimox (5-methylpyrazinecarboxylic acid 4-oxide) is a new lipolysis inhibitor that has a distant chemical relationship with nicotinic acid (NA). The anti-lipolytic action of acipimox is mediated through suppression of intracellular cyclic AMP levels, with the subsequent decrease in cyclic AMP-dependent protein kinase activity, leading to the reduced association of hormone-sensitive lipase with triacylglycerol substrate in the lipid droplet of adipocytes. Acipimox has been identified as an agonist at G-protein coupled nicotinic acid HM74A and HM74B receptors. Acipimox (Olbetam) is indicated for the treatment as alternative or adjunct treatment to reduce triglyceride levels in patients who have not responded adequately to other treatments such as statin or fibrate treatment for hypertriglyceridaemia (Fredrickson type IV hyperlipoproteinaemia) and hypercholesterolaemia and hypertriglyceridaemia (Fredrickson type IIb hyperlipoproteinaemia).
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nicofuranose is a niacin derivative used as a hypolipidemic agent. The Nicofuranose administration leads to inhibition of free fatty acid turnover and consequently a marked reduction in triglyceride turnover. Nicofuranose, unlike clofibrate, did not affect the mechanisms responsible for the clearance of plasma triglycerides.
Status:
Discontinued
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Other
Class:
MIXTURE
